Monitoring antifolate resistance in intermittent preventive therapy for malaria
- PMID: 23948432
- PMCID: PMC3810209
- DOI: 10.1016/j.pt.2013.07.008
Monitoring antifolate resistance in intermittent preventive therapy for malaria
Abstract
Mutations in the Plasmodium falciparum genes Pfdhfr and Pfdhps have rendered sulfadoxine-pyrimethamine (SP) ineffective for malaria treatment in most regions of the world. Yet, SP is efficacious as intermittent preventive therapy in pregnant women (IPTp) and infants (IPTi) and as seasonal malaria control in children (SMC). SP-IPTp is being widely implemented in sub-Saharan Africa. SP-IPTi is recommended where the prevalence of SP-resistant malaria parasites is low, whereas SMC is recommended for areas of intense seasonal malaria transmission. The continuing success of these interventions depends largely on the prevalence of Pfdhfr and Pfdhps resistance mutations in the target population. Here we review the relationship between resistance mutations and SP-IPT within target populations in the context of monitoring and informing implementation of this intervention.
Copyright © 2013 Elsevier Ltd. All rights reserved.
References
-
- Peters W. Chemotherapy and drug resistance in malaria. Academic Press; 1987.
-
- Vleugels MP, et al. Fansidar-resistant Plasmodium falciparum infection from Tanzania. Trop. Geogr. Med. 1982;34:263–265. - PubMed
-
- Stahel E, et al. Pyrimethamine/sulfadoxine resistant falciparum malaria acquired at Dar es Salaam, Tanzania. Lancet. 1982;1:1118–1119. - PubMed
-
- Charmot G, et al. 2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation. Bull. Soc. Pathol. Exot. Filiales. 1987;80:447–451. - PubMed
-
- Kupferschmidt HG, et al. Chloroquine and fansidar resistance of Plasmodium falciparum now also in Ghana. Angew. Parasitol. 1988;29:211–213. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources